CDKN1B and prostate carcinoma: Similarly, the prediction results for CDKN1B sensitivity (50% inhibitory concentration, IC50) suggested that the CDKN1B high expression group was more sensitive to JQ1_2172 drugs and common chemotherapy drugs for prostate cancer, such as Gemcitabine and Docetaxel.